Your trusted source for investing success
By Shelly Kumar
Valens GroWorks (CSE:VGW)(CSE:VGW.CN) (the “Company” or “Valens“) is pleased to announce that Mr. Saul Katz has joined the Company as its President.
Mr. Katz brings to Valens 35 years of entrepreneurship, senior management experience and scientific expertise in functional food product development and commercialization. Over his career he established research collaborations with leading
By Melissa Shaw
The company will supply a planned 15GWh lithium-ion battery gigafactory in New York with anode materials and technologies.
Beleave Inc. (“Beleave”) (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it will begin a clinical research program with Dr. Mohit Bhandari, to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorders. In North America, Europe, and Australia, chronic non-cancer pain is a
By Pia Rivera
An update on the major issues affecting technology companies under the Trump presidency.
By Emma Harwood
Wi2Wi Corporation (TSXV:YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors.
As quoted
Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to provide a development update on its FAIMS Beta 2.0 (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer for the detection of ∆9-tetrahydrocannabinol (“THC”) in human
The company bought the remaining stake in the Mutanda mine and increased its interest in Katanga mine.
2016 saw countless pharmaceutical companies taken to task for price gouging. Close to the end of the year, a related topic made headlines: price collusion, this time among generic drug manufacturers.
Novelion Therapeutics, a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsidiary of Novelion, entered into an agreement in principle to settle all claims in the class action shareholder lawsuit pending
By Nick Smith
Mining Journal’s Best Americas Based Fund Manager tells us about the four-year gold cycle, the current correction phase, the Trump impact on the economy and where gold will be in 2017.
At close of trading yesterday, Mylan (NASDAQ:MYL) was down 6.9 percent, Teva (NYSE:TEVA) had lost 9.5 percent and Endo International (TSX:ENL) dropped close to twenty percent.
As we predicted several weeks ago, Mylan isn’t out of hot water yet: the embattled pharmaceutical giant now faces a class action lawsuit from shareholders.
Mylan announced on October 7, 2016, that they will pay a $465 million settlement to the US federal government, clearing the company of any rebate liability going forward.
HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development operations
with a primary focus in Hematology and Oncology, today announced that it
has settled its ANDA patent litigation relating to FOLOTYN. As a result
of the settlement with the last remaining ANDA filer, Fresenius Kabi
USA, LLC, and
Identillect Technologies Corp. (TSXV:ID) and Accessible Compliance have announced a new partnership in the United States. Their reseller partnership provides Identillect with access to hundreds of commercial businesses searching for a solution to remain compliant with state, federal and industry data handling regulations.
According to the press release:
Accessible Compliance is in the process of
CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) — Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that it has reached preliminary agreements in principle with the Department of Justice (
The real story behind the renewable energy company’s bankruptcy filing.
Apple’s standoff with the FBI over privacy has increased cybersecurity awareness.
By Vivien Diniz
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has entered into a settlement agreement with the United States Securities and Exchange Commission (SEC) fully resolving the SEC’s investigation into possible violations of the Foreign Corrupt Practices Act (FCPA).
After hours Friday, Kinross Gold Corp. (TSX:K,NYSE:KGC) put out a press release to address “the circumstances surrounding an ongoing regulatory review” of its mining operations in West Africa.
